Get access

Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks

Authors

  • L. Naldi,

    1. Clinica Dermatologica, Ospedali Riuniti, Largo Barozzi, 1-24128 Bergamo, Italy
      *Dermatology Centre, Hope Hospital, University of Manchester, Manchester M6 8HD, U.K.
    Search for more papers by this author
  • C.E.M. Griffiths

    1. Clinica Dermatologica, Ospedali Riuniti, Largo Barozzi, 1-24128 Bergamo, Italy
      *Dermatology Centre, Hope Hospital, University of Manchester, Manchester M6 8HD, U.K.
    Search for more papers by this author

  • Conflicts of interest: This study was funded in part by Serono International SA.

Luigi Naldi.
E-mail: luigi.naldi@gised.it

Summary

Psoriasis is a chronic, recurrent disease that affects between 1% and 3% of the population. Patients with moderate to severe disease generally require phototherapy (e.g. narrowband ultraviolet B radiation), photochemotherapy (oral psoralen plus ultraviolet A radiation) or systemic agents (e.g. ciclosporin, methotrexate, oral retinoids, fumaric acid esters) to control their disease adequately. In general, these therapeutic modalities have proven to be highly effective in the treatment of psoriasis. However, potentially serious toxicities can limit their long-term use. Given that there is no standard therapeutic approach for patients with moderate to severe psoriasis, the benefits and risks of phototherapy, photochemotherapy and systemic therapy must be weighed carefully for each patient, and treatment individualized accordingly. This review summarizes the benefits and risks of traditional, nonbiological therapies for moderate to severe chronic plaque psoriasis.

Ancillary